Thursday, October 22, 2020

H.C. Wainwright lifts Clovis Oncology Inc. [CLVS] price estimate. Who else is bullish?

Must read

Chevron Corporation [CVX] is -40.52% lower this YTD. Is it still time to buy?

Chevron Corporation traded at a high on 10/20/20, posting a 0.56 gain after which it closed the day’ session at $71.68. The company...

Atlantic Equities lifts Thermo Fisher Scientific Inc. [TMO] price estimate. Who else is bullish?

Thermo Fisher Scientific Inc. jumped around 4.03 points on Friday, while shares priced at $468.59 at the close of the session, up 0.87%....

Pioneer Power Solutions Inc. [PPSI] stock Reiterated by ROTH Capital analyst, price target now $6

Pioneer Power Solutions Inc. plunged by -$0.23 during the normal trading session on Wednesday and reaching a high of $3.74 during the day...

For Fifth Third Bancorp [FITB], Morgan Stanley sees a rise to $30. What next?

Fifth Third Bancorp loss -1.69% or -0.39 points to close at $22.73 with a heavy trading volume of 6508439 shares. The company report...

Clovis Oncology Inc. [NASDAQ: CLVS] price plunged by -4.61 percent to reach at -$0.27.

A sum of 4551611 shares traded at recent session while its average daily volume was at 4.82M shares. Clovis Oncology Inc. shares reached a high of $5.97 and dropped to a low of $5.54 until finishing in the latest session at $5.70.

The one-year CLVS stock forecast points to a potential upside of 36.67. The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Clovis Oncology Inc. [CLVS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.

The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.58, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 3.38.

CLVS Stock Performance Analysis:

Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.86. With this latest performance, CLVS shares gained by 11.89% in over the last four-week period, additionally plugging by 5.46% over the last 6 months – not to mention a rise of 36.24% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 44.30, with the RSI for the last a single of trading hit 39.46, and the three-weeks RSI is set at 46.41 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 5.87, while it was recorded at 6.53 for the last single week of trading, and 7.54 for the last 200 days.

Insight into Clovis Oncology Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -256.85 and a Gross Margin at +75.75. Clovis Oncology Inc.’s Net Margin is presently recorded at -280.01.

Return on Total Capital for CLVS is now -58.15, given the latest momentum, and Return on Invested Capital for the company is -63.72. Additionally, CLVS Total Debt to Total Capital is recorded at 132.25, with Total Debt to Total Assets ending up at 106.72.

Reflecting on the efficiency of the workforce at the company, Clovis Oncology Inc. [CLVS] managed to generate an average of -$827,322 per employee. Receivables Turnover for the company is 5.74 with a Total Asset Turnover recorded at a value of 0.19.Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.90.


With the latest financial reports released by the company, Clovis Oncology Inc. posted -1.72/share EPS, while the average EPS was predicted by analysts to be reported at -1.89/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clovis Oncology Inc. go to 66.10%.

Clovis Oncology Inc. [CLVS] Insider Position Details

There are presently around $269 million, or 55.10% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 9,238,731, which is approximately 151.719% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 6,244,924 shares of the stock with an approximate value of $35.56 million in CLVS stocks shares; and BLACKROCK INC., currently with $32.03 million in CLVS stock with ownership of nearly 48.319% of the company’s market capitalization.

Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 99 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 18,661,399 shares. Additionally, 67 investors decreased positions by around 5,804,789 shares, while 25 investors held positions by with 22,764,143 shares. The mentioned changes placed institutional holdings at 47,230,331 shares, according to the latest SEC report filing. CLVS stock had 36 new institutional investments in for a total of 5,037,081 shares, while 30 institutional investors sold positions of 2,201,668 shares during the same period.

More articles


Please enter your comment!
Please enter your name here

Latest article

Titan Pharmaceuticals Inc. [TTNP] is -39.31% lower this YTD. Is it still time to buy?

Titan Pharmaceuticals Inc. slipped around -0.02 points on Tuesday, while shares priced at $0.12 at the close of the session, down -14.33%. The...

For Tyson Foods Inc. [TSN], Credit Suisse sees a drop to $68. What next?

Tyson Foods Inc. stock went on a downward path that fall over -0.77% on Tuesday, amounting to a one-week price decrease of less...

Market Analysts see Alliance Data Systems Corporation [ADS] gaining to $67. Time to buy?

Alliance Data Systems Corporation loss -4.55% on the last trading session, reaching $51.76 price per share at the time. The company report on...

Robert Half International Inc. [RHI] Revenue clocked in at $5.70 billion, down -10.85% YTD: What’s Next?

Robert Half International Inc. surged by $0.87 during the normal trading session on Tuesday and reaching a high of $57.31 during the day...

Foot Locker Inc. [FL] Is Currently 1.35 below its 200 Period Moving Avg: What Dose This Mean?

Foot Locker Inc. traded at a high on 10/20/20, posting a 1.35 gain after which it closed the day’ session at $38.37. The...